,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2020', 'fs': 'Jul 2020', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000007Jz52UAC'}, 'Id': 'a0P2P000007Jz52UAC', 'Event_Date__c': '2020-07-24', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Jul 2020', 'Status_History__c': 'a132P000000CWYKQA4'}, 'change': None}]",Jul 2020,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2021', 'fs': 'Jan 2021', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000007Jz53UAC'}, 'Id': 'a0P2P000007Jz53UAC', 'Event_Date__c': '2021-01-19', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jan 2021', 'Status_History__c': 'a132P000000CWYPQA4'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2021', 'fs': 'Oct 2021', 'change': None}, 'Event_Description': {'s': 'Assigned to Reproductive and Sexual Health Subcommittee meeting to provide advice on Monday 1 November 2021', 'fs': 'Assigned to Reproductive and Sexual Health Subcommittee meeting to provide advice on Monday 1 November 2021', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000007Jz54UAC'}, 'Id': 'a0P2P000007Jz54UAC', 'Event_Date__c': '2021-10-01', 'Event_Description__c': 'Assigned to Reproductive and Sexual Health Subcommittee meeting to provide advice on Monday 1 November 2021', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Oct 2021', 'Status_History__c': 'a132P000000DDJ8QAO'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>The Subcommittee <b>recommended</b> that riboflavin for perioperative use for the assessment of ureteric patency during cystoscopy be listed with a high priority within the context of treatment in reproductive and sexual health, subject to the following Special Authority criteria: </p><p><br></p><p>Initial Application. Applications valid for 3 months for applications meeting the following criteria: </p><p>1 Patient is scheduled for assessment of ureteric patency during cystoscopy </p><p><br></p><p>The Subcommittee made this recommendation based on the favourable safety, reduced risk of adverse reactions, and mode of administration of riboflavin compared to current options.</p>', 'fs': '<p>The Subcommittee <b>recommended</b> that riboflavin for perioperative use for the assessment of ureteric patency during cystoscopy be listed with a high priority within the context of treatment in reproductive and sexual health, subject to the following Special Authority criteria: </p><p><br></p><p>Initial Application. Applications valid for 3 months for applications meeting the following criteria: </p><p>1 Patient is scheduled for assessment of ureteric patency during cystoscopy </p><p><br></p><p>The Subcommittee made this recommendation based on the favourable safety, reduced risk of adverse reactions, and mode of administration of riboflavin compared to current options.</p>', 'change': None}, 'Published_Discussion': {'s': '<p>The Subcommittee noted that cystoscopy is undertaken for various reasons, but that this application relates specifically to patients undergoing assessment of ureteric patency during cystoscopy, and that the riboflavin is not intended to be therapeutic. The Subcommittee noted also that there are currently no funded oral agents to induce colouration to the urine to assist in visualising the ureteric jets at the time of intraoperative cystoscopy. The Subcommittee noted that intravenous indigo carmine, methylthioninium chloride (methylene blue), or fluorescein are used in this setting, and that indigo carmine is not an approved product and that fluorescein is used off-label for this indication.</p><p><br></p><p>The Subcommittee noted that currently available treatments are administered intravenously and pose a higher risk of adverse events such as anaphylaxis, which requires monitoring post-administration.</p><p><br></p><p>The Subcommittee noted that the applicant proposed that 400 mg riboflavin would be taken orally the night before surgery to colour the urine, for improved visualisation of vesicoureteric anatomy. The Subcommittee noted that, as an endogenous vitamin, oral riboflavin does not pose the same level of risk compared with other coloured intravenous agents. The Subcommittee also noted that there is evidence of riboflavin being used for this purpose in the following studies:</p><p><br></p><p class=""ql-indent-1""><a href=""https://pubmed.ncbi.nlm.nih.gov/30633139/"" target=""_blank"">Stitely et al. Obstet Gynecol. 2019;133:301-7</a>: a randomised controlled trial of patients scheduled for gynaecologic surgery where cystoscopy was a planned component of the procedure who were given 400 mg of riboflavin versus placebo the night before surgery. Patients had significantly increased coloured urine, ureteral jets were more easily visualised, and that bilateral ureteric patency was confirmed in 30 of 33 women (91%) in the riboflavin group and in 28 of 33 women (85%) in the placebo group (P=0.71).</p><p class=""ql-indent-1""><br></p><p class=""ql-indent-1""><a href=""https://pubmed.ncbi.nlm.nih.gov/21472446/"" target=""_blank"">Fernando et al. Int Urogynexol J. 2011;22:947-51</a>: an observational study of women booked to receive cystoscopy as main procedure or were likely to require one as an adjunct to vaginal surgery who were given three vitamin B complex tablets 1-4 hours prior to cystoscopy (total 45 mg riboflavin). 72.1% participants had yellow-coloured urine and indigo carmine was only used twice (2.9%); one of which was due to clinician preference.</p><p class=""ql-indent-1""><br></p><p>The Subcommittee noted that the applicant also provided a case report study of an individual who had anaphylactic shock after administration of intravenous sodium fluorescein for the assessment of ureteral efflux <a href=""https://pubmed.ncbi.nlm.nih.gov/29528930/"" target=""_blank"">(Lee et al. Obstet Gynecol. 2018;131:727-9).</a></p><p><br></p><p>The Subcommittee noted that the number of patients who might require riboflavin for assessment of ureteric patency during cystoscopy was unknown and considered that funding riboflavin would result in its use in a minority of procedures and would not lead to a significant uptake by clinicians. The Subcommittee considered that from a gynaecological perspective the majority of patients undergoing cystoscopy would require visualisation as a part of their procedure. Members were not aware if this proportion differed substantially in urology practice. The Subcommittee considered that including patients undergoing cystoscopy or hysterectomy would give the largest possible potential patient population.</p><p><br></p><p>The Subcommittee considered that using riboflavin for this purpose would reduce the requirement for intravenous administration of agents and thus reduce the risk of anaphylactic reactions. While this might reduce the requirement for monitoring for the latter, it was noted that, as patients are routinely monitored perioperatively regardless of agent used, this would not impact hugely on clinician time. The Subcommittee also considered that careful planning would be needed to provide patients with the riboflavin in advance of cystoscopy, as they would take it at home, the night before the procedure. However, because patients undergo some form of preadmission process prior to these procedures, this should not pose a barrier to its use</p><p><br></p><p>The Subcommittee considered that the below table summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for riboflavin if it were to be funded in New Zealand for perioperative use for cystoscopy. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Subcommittee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</p><p><br></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0P2P000007Jz55&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000001sGvv"" alt=""image.png""></img></p>', 'fs': '<p>The Subcommittee noted that cystoscopy is undertaken for various reasons, but that this application relates specifically to patients undergoing assessment of ureteric patency during cystoscopy, and that the riboflavin is not intended to be therapeutic. The Subcommittee noted also that there are currently no funded oral agents to induce colouration to the urine to assist in visualising the ureteric jets at the time of intraoperative cystoscopy. The Subcommittee noted that intravenous indigo carmine, methylthioninium chloride (methylene blue), or fluorescein are used in this setting, and that indigo carmine is not an approved product and that fluorescein is used off-label for this indication.</p><p><br></p><p>The Subcommittee noted that currently available treatments are administered intravenously and pose a higher risk of adverse events such as anaphylaxis, which requires monitoring post-administration.</p><p><br></p><p>The Subcommittee noted that the applicant proposed that 400 mg riboflavin would be taken orally the night before surgery to colour the urine, for improved visualisation of vesicoureteric anatomy. The Subcommittee noted that, as an endogenous vitamin, oral riboflavin does not pose the same level of risk compared with other coloured intravenous agents. The Subcommittee also noted that there is evidence of riboflavin being used for this purpose in the following studies:</p><p><br></p><p class=""ql-indent-1""><a href=""https://pubmed.ncbi.nlm.nih.gov/30633139/"" target=""_blank"">Stitely et al. Obstet Gynecol. 2019;133:301-7</a>: a randomised controlled trial of patients scheduled for gynaecologic surgery where cystoscopy was a planned component of the procedure who were given 400 mg of riboflavin versus placebo the night before surgery. Patients had significantly increased coloured urine, ureteral jets were more easily visualised, and that bilateral ureteric patency was confirmed in 30 of 33 women (91%) in the riboflavin group and in 28 of 33 women (85%) in the placebo group (P=0.71).</p><p class=""ql-indent-1""><br></p><p class=""ql-indent-1""><a href=""https://pubmed.ncbi.nlm.nih.gov/21472446/"" target=""_blank"">Fernando et al. Int Urogynexol J. 2011;22:947-51</a>: an observational study of women booked to receive cystoscopy as main procedure or were likely to require one as an adjunct to vaginal surgery who were given three vitamin B complex tablets 1-4 hours prior to cystoscopy (total 45 mg riboflavin). 72.1% participants had yellow-coloured urine and indigo carmine was only used twice (2.9%); one of which was due to clinician preference.</p><p class=""ql-indent-1""><br></p><p>The Subcommittee noted that the applicant also provided a case report study of an individual who had anaphylactic shock after administration of intravenous sodium fluorescein for the assessment of ureteral efflux <a href=""https://pubmed.ncbi.nlm.nih.gov/29528930/"" target=""_blank"">(Lee et al. Obstet Gynecol. 2018;131:727-9).</a></p><p><br></p><p>The Subcommittee noted that the number of patients who might require riboflavin for assessment of ureteric patency during cystoscopy was unknown and considered that funding riboflavin would result in its use in a minority of procedures and would not lead to a significant uptake by clinicians. The Subcommittee considered that from a gynaecological perspective the majority of patients undergoing cystoscopy would require visualisation as a part of their procedure. Members were not aware if this proportion differed substantially in urology practice. The Subcommittee considered that including patients undergoing cystoscopy or hysterectomy would give the largest possible potential patient population.</p><p><br></p><p>The Subcommittee considered that using riboflavin for this purpose would reduce the requirement for intravenous administration of agents and thus reduce the risk of anaphylactic reactions. While this might reduce the requirement for monitoring for the latter, it was noted that, as patients are routinely monitored perioperatively regardless of agent used, this would not impact hugely on clinician time. The Subcommittee also considered that careful planning would be needed to provide patients with the riboflavin in advance of cystoscopy, as they would take it at home, the night before the procedure. However, because patients undergo some form of preadmission process prior to these procedures, this should not pose a barrier to its use</p><p><br></p><p>The Subcommittee considered that the below table summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for riboflavin if it were to be funded in New Zealand for perioperative use for cystoscopy. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Subcommittee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</p><p><br></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0P2P000007Jz55&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000001sGvv"" alt=""image.png""></img></p>', 'change': None}, 'Published_Application': {'s': '<p>The Subcommittee considered a clinician application for riboflavin (vitamin B2) for perioperative use for the assessment of ureteric patency during cystoscopy.</p>', 'fs': '<p>The Subcommittee considered a clinician application for riboflavin (vitamin B2) for perioperative use for the assessment of ureteric patency during cystoscopy.</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2022', 'fs': 'Feb 2022', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Reproductive and Sexual Health Subcommittee at meeting Monday 1 November 2021.', 'fs': 'Clinical advice received from Reproductive and Sexual Health Subcommittee at meeting Monday 1 November 2021.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000007Jz55UAC'}, 'Id': 'a0P2P000007Jz55UAC', 'Event_Date__c': '2022-02-11', 'Event_Description__c': 'Clinical advice received from Reproductive and Sexual Health Subcommittee at meeting Monday 1 November 2021.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'High', 'Formatted_Date__c': 'Feb 2022', 'Published_Recommendation__c': '<p>The Subcommittee <b>recommended</b> that riboflavin for perioperative use for the assessment of ureteric patency during cystoscopy be listed with a high priority within the context of treatment in reproductive and sexual health, subject to the following Special Authority criteria: </p><p><br></p><p>Initial Application. Applications valid for 3 months for applications meeting the following criteria: </p><p>1 Patient is scheduled for assessment of ureteric patency during cystoscopy </p><p><br></p><p>The Subcommittee made this recommendation based on the favourable safety, reduced risk of adverse reactions, and mode of administration of riboflavin compared to current options.</p>', 'Published_Application__c': '<p>The Subcommittee considered a clinician application for riboflavin (vitamin B2) for perioperative use for the assessment of ureteric patency during cystoscopy.</p>', 'Published_Discussion__c': '<p>The Subcommittee noted that cystoscopy is undertaken for various reasons, but that this application relates specifically to patients undergoing assessment of ureteric patency during cystoscopy, and that the riboflavin is not intended to be therapeutic. The Subcommittee noted also that there are currently no funded oral agents to induce colouration to the urine to assist in visualising the ureteric jets at the time of intraoperative cystoscopy. The Subcommittee noted that intravenous indigo carmine, methylthioninium chloride (methylene blue), or fluorescein are used in this setting, and that indigo carmine is not an approved product and that fluorescein is used off-label for this indication.</p><p><br></p><p>The Subcommittee noted that currently available treatments are administered intravenously and pose a higher risk of adverse events such as anaphylaxis, which requires monitoring post-administration.</p><p><br></p><p>The Subcommittee noted that the applicant proposed that 400 mg riboflavin would be taken orally the night before surgery to colour the urine, for improved visualisation of vesicoureteric anatomy. The Subcommittee noted that, as an endogenous vitamin, oral riboflavin does not pose the same level of risk compared with other coloured intravenous agents. The Subcommittee also noted that there is evidence of riboflavin being used for this purpose in the following studies:</p><p><br></p><p class=""ql-indent-1""><a href=""https://pubmed.ncbi.nlm.nih.gov/30633139/"" target=""_blank"">Stitely et al. Obstet Gynecol. 2019;133:301-7</a>: a randomised controlled trial of patients scheduled for gynaecologic surgery where cystoscopy was a planned component of the procedure who were given 400 mg of riboflavin versus placebo the night before surgery. Patients had significantly increased coloured urine, ureteral jets were more easily visualised, and that bilateral ureteric patency was confirmed in 30 of 33 women (91%) in the riboflavin group and in 28 of 33 women (85%) in the placebo group (P=0.71).</p><p class=""ql-indent-1""><br></p><p class=""ql-indent-1""><a href=""https://pubmed.ncbi.nlm.nih.gov/21472446/"" target=""_blank"">Fernando et al. Int Urogynexol J. 2011;22:947-51</a>: an observational study of women booked to receive cystoscopy as main procedure or were likely to require one as an adjunct to vaginal surgery who were given three vitamin B complex tablets 1-4 hours prior to cystoscopy (total 45 mg riboflavin). 72.1% participants had yellow-coloured urine and indigo carmine was only used twice (2.9%); one of which was due to clinician preference.</p><p class=""ql-indent-1""><br></p><p>The Subcommittee noted that the applicant also provided a case report study of an individual who had anaphylactic shock after administration of intravenous sodium fluorescein for the assessment of ureteral efflux <a href=""https://pubmed.ncbi.nlm.nih.gov/29528930/"" target=""_blank"">(Lee et al. Obstet Gynecol. 2018;131:727-9).</a></p><p><br></p><p>The Subcommittee noted that the number of patients who might require riboflavin for assessment of ureteric patency during cystoscopy was unknown and considered that funding riboflavin would result in its use in a minority of procedures and would not lead to a significant uptake by clinicians. The Subcommittee considered that from a gynaecological perspective the majority of patients undergoing cystoscopy would require visualisation as a part of their procedure. Members were not aware if this proportion differed substantially in urology practice. The Subcommittee considered that including patients undergoing cystoscopy or hysterectomy would give the largest possible potential patient population.</p><p><br></p><p>The Subcommittee considered that using riboflavin for this purpose would reduce the requirement for intravenous administration of agents and thus reduce the risk of anaphylactic reactions. While this might reduce the requirement for monitoring for the latter, it was noted that, as patients are routinely monitored perioperatively regardless of agent used, this would not impact hugely on clinician time. The Subcommittee also considered that careful planning would be needed to provide patients with the riboflavin in advance of cystoscopy, as they would take it at home, the night before the procedure. However, because patients undergo some form of preadmission process prior to these procedures, this should not pose a barrier to its use</p><p><br></p><p>The Subcommittee considered that the below table summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for riboflavin if it were to be funded in New Zealand for perioperative use for cystoscopy. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Subcommittee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</p><p><br></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0P2P000007Jz55&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000001sGvv"" alt=""image.png""></img></p>', 'Status_History__c': 'a132P000000DXE7QAO'}, 'change': None}]",Jan 2021,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2022', 'fs': 'Feb 2022', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000007Jz56UAC'}, 'Id': 'a0P2P000007Jz56UAC', 'Event_Date__c': '2022-02-24', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Feb 2022', 'Status_History__c': 'a132P000000EDaMQAW'}, 'change': None}]",Feb 2022,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2023', 'fs': 'Jun 2023', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0P2P000007Jz57UAC'}, 'Id': 'a0P2P000007Jz57UAC', 'Event_Date__c': '2023-06-12', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2023', 'Status_History__c': 'a132P000000EOPOQA4'}, 'change': None}]",Jun 2023,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
